Author

G. Olivier

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1 Assay:protein sequence· 1

Frequent Co-Authors

A. Alasonyalilar Demirer· 1 shared A. Drelich· 1 shared A. Zubair· 1 shared B. L. Kimball· 1 shared B. Parrett· 1 shared C. Erskine· 1 shared C. M. Stewart· 1 shared C. Manriquez-Roman· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Alasonyalilar Demirer

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Optimized CART Cell Therapy for Metastatic Aggressive Thyroid Cancer

C. Manriquez-Roman, E. L. Siegler, J. J. Gleba, T. N. Huynh, G. E. DeFranco, A. Alasonyalilar Demirer, M. L. Pawlush, M. Redig, S. M. Klinge, L. K. Mai, J. L. Miller, E. E. Miller, B. L. Kimball, E. E. Tapper, R. L. Sakemura, , S. S. Kenderian

This paper develops a TSHR-targeted CART cell therapy for thyroid cancer and shows that combining it with MAPK inhibitors improves antitumor efficacy in dedifferentiated thyroid cancers.

bioRxiv · Mar 15, 2024 · PreprintImmunology

Comparison of Mucosal and Intramuscular Immunization against SARS-CoV-2 with Replication-Defective and Replicating Single-cycle Adenovirus Vaccines

M. A. Barry, H. Mudrick, E. McGlinch, B. Parrett, J. Hemsath, M. Barry, J. Rubin, C. Uzendu, M. Hansen, C. Erskine, V. VanKeulen, A. Drelich, C.-T. K. Tseng, C. S. Massey, M. Fida, , G. Olivier

This study compares mucosal and intramuscular immunization with replication-defective and replicating single-cycle adenovirus vaccines against SARS-CoV-2, showing that replicating vaccines generate stronger antibody responses.

bioRxiv · Apr 20, 2021 · PreprintImmunology